FY2018 EPS Estimates for Medpace Holdings Inc (MEDP) Boosted by Analyst
Medpace Holdings Inc (NASDAQ:MEDP) – Mitsubishi UFJ Financial Group increased their FY2018 earnings estimates for shares of Medpace in a report released on Thursday, November 8th. Mitsubishi UFJ Financial Group analyst J. Twizell now expects that the company will post earnings of $2.56 per share for the year, up from their previous estimate of $2.48. Mitsubishi UFJ Financial Group also issued estimates for Medpace’s Q4 2018 earnings at $0.73 EPS, Q2 2019 earnings at $0.74 EPS, Q4 2019 earnings at $0.80 EPS, FY2019 earnings at $2.96 EPS and FY2020 earnings at $3.38 EPS.
A number of other brokerages have also commented on MEDP. SunTrust Banks began coverage on shares of Medpace in a research report on Monday, September 17th. They set a “hold” rating and a $63.00 price objective for the company. BidaskClub raised shares of Medpace from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, September 12th. Credit Suisse Group upped their price objective on shares of Medpace from $42.00 to $49.00 and gave the company an “outperform” rating in a research report on Tuesday, July 31st. Zacks Investment Research raised shares of Medpace from a “hold” rating to a “strong-buy” rating and set a $69.00 price objective for the company in a research report on Friday, August 3rd. Finally, TheStreet raised shares of Medpace from a “c” rating to a “b-” rating in a research report on Friday, August 10th. Four analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Medpace currently has a consensus rating of “Buy” and a consensus target price of $44.43.
Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Thursday, November 1st. The company reported $0.67 EPS for the quarter, beating the Zacks’ consensus estimate of $0.63 by $0.04. The business had revenue of $179.00 million during the quarter, compared to analyst estimates of $175.07 million. Medpace had a net margin of 10.84% and a return on equity of 15.86%. The firm’s revenue for the quarter was up 44.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.40 earnings per share.
In related news, major shareholder Medpace Limited Partnership sold 5,224,997 shares of the stock in a transaction dated Monday, August 27th. The shares were sold at an average price of $54.75, for a total value of $286,068,585.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Medpace Investors, Llc sold 132,304 shares of the stock in a transaction dated Thursday, September 27th. The stock was sold at an average price of $58.58, for a total transaction of $7,750,368.32. Following the completion of the transaction, the insider now directly owns 8,989,174 shares of the company’s stock, valued at approximately $526,585,812.92. The disclosure for this sale can be found here. Insiders sold 5,621,556 shares of company stock valued at $309,490,974 in the last three months. Company insiders own 29.50% of the company’s stock.
A number of large investors have recently bought and sold shares of the stock. BlackRock Inc. raised its position in Medpace by 42.1% in the third quarter. BlackRock Inc. now owns 2,282,063 shares of the company’s stock worth $136,719,000 after purchasing an additional 676,396 shares in the last quarter. Acadian Asset Management LLC raised its position in Medpace by 14.2% in the third quarter. Acadian Asset Management LLC now owns 1,464,121 shares of the company’s stock worth $87,717,000 after purchasing an additional 182,588 shares in the last quarter. Laurion Capital Management LP raised its position in Medpace by 63.1% in the third quarter. Laurion Capital Management LP now owns 1,108,556 shares of the company’s stock worth $66,414,000 after purchasing an additional 428,785 shares in the last quarter. Renaissance Technologies LLC raised its position in Medpace by 131.6% in the third quarter. Renaissance Technologies LLC now owns 784,900 shares of the company’s stock worth $47,023,000 after purchasing an additional 446,000 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. acquired a new position in Medpace in the third quarter worth about $37,292,000. 42.40% of the stock is owned by hedge funds and other institutional investors.
Medpace Company Profile
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
Read More: Marijuana Stocks
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.